Antithrombin activity during the period of percutaneous coronary revascularization: Relation to heparin use, thrombotic complications and restenosis

Journal of the American College of Cardiology

Volumn 33, Issue 5, 1999, Pages 1248-1256

  Matthai Jr , William H ^a   Kurnik, Peter B ^b   Groh, William C ^a   Untereker, William J ^a   Siegel, Jamie E ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARIN;

ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBINS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY THROMBOSIS; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033117019     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00696-2     Document Type: Article

References (28)

1. Laskey M.A.L., Deutsch E., Barnathan E., Laskey W.K. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris. Am J Cardiol. 65:1990;1425-1429.
2. Theroux P., Waters D., Lam J., Juneau M., McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 327:1992;141-145.
3. Granger C.B., Miller J.M., Bovill E.G., et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation. 91:1995;1929-1935.
4. Smith A.J.C., Holt R.E., Fitzpatrick K., et al. Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Am Heart J. 131:1996;434-439.
5. Marciniak E., Gockerman J.P. Heparin-induced decrease in circulating antithrombin-III. Lancet. 2:1977;581-584.
6. Rao A.K., Guzzo J., Niewiarowski S., Day H.J. Antithrombin-III levels during heparin therapy. Thromb Res. 24:1981;181-186.
7. Lidon R.M., Theroux P., Robitaille D. Antithrombin-III plasma activity during and after prolonged use of heparin in unstable angina. Thromb Res. 72:1993;23-32.
8. Blajchman MA, Austin RC, Fernandez Rachubinski F, Sheffield WP. Molecular basis of inherited human antithrombin deficiency. Blood 1992;80;9:2159-71.
9. Lincoff A.M., Popma J.J., Ellis S.G., Hacker J.A., Topol E.J. Abrupt vessel closure complicating coronary angioplasty clinical, angiographic and therapeutic profile . J Am Coll Cardiol. 19:1992;926-935.
10. Ryan T.J., Faxon D.P., Gunnar R.M., et al. Guidelines for percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 12:1988;529-545.
11. Grines C.L., Schreiber T.L., Savas V., et al. A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 27:1996;1381-1386.
12. Weitz J.I., Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin-III but is susceptible to inactivation by antithrombin-III-independent inhibitors. J Clin Invest. 86:1990;385-391.
13. Meyer B.J., Badimon J.J., Mailhac A., et al. Inhibition of growth of thrombus on fresh mural thrombus. Circulation. 90:1994;2432-2438.
14. Weitz J.I., Leslie B., Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation. 97:1998;544-552.
15. Oltrona L., Eisenberg P.R., Lasala J.M., Sewall D.J., Shelton M.E., Winters K.J. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation. 94:1996;2064-2071.
16. Winters K.J., Smith S.C., Eisenberg P.R. Heparin-resistant thrombin activity in coronary dissection and threatened coronary occlusion during coronary interventions. [Abstr] J Am Coll Cardiol. 31:1998;403A.
17. Bar-Shavit R., Eldor A., Voldavsky I. Binding of thrombin to subendothelial extracellular matrix. J Clin Invest. 84:1989;1096-1104.
18. Laskey M.A.L., Deutsch E., Hirshfeld J.W. Jr, Kussmaul W.G., Barnathan E., Laskey W.K. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol. 65:1990;179-182.
19. Klein L.W., Wahid F., VandenBerg B.J., Parrillo J.E., Calvin J.E. Comparison of heparin therapy for <48 hours to >48 hours in unstable angina pectoris. Am J Cardiol. 79:1997;259-263.
20. Grip L., Blomback M., Egberg N., Olsson A., Svane B., Velander M. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. Eur Heart J. 18:1997;443-449.
21. Kobayashi H., Suzuki S., Sakamoto S., Matsuo T. Argatroban, a direct thrombin inhibitor versus heparin during and after percutaneous transluminal coronary angioplasty (PTCA). [Abstr] Thromb Haemost. (Suppl):1997;494.
22. Unterberg C., Sandrock D., Nebendahl K., Buchwald A.B. Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. J Am Coll Cardiol. 26:1995;1747-1754.
23. Gallo R, Padurean A, Toschi V, et al. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. Circulation 1198;97:581-8.
24. Hedin U., Frebelius S., Sanchez J., Dryjski M., Swedenborg J. Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells. Arterioscler Thromb. 14:1994;254-260.
25. Serruys P.W., Herrman J.P.R., Simon R., et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 333:1995;757-763.
26. Bittl J.A., Strony J., Brinker J.A., et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 333:1995;764-769.
27. DeStefano V., Finazzi G., Mannucci P. Inherited thrombophilia pathogenesis, clinical syndromes, and management . Blood. 87:1996;3531-3544.
28. Schachinger V., Allert M., Kasper W., Just H., Vach W., Zeiher A.M. Adjunctive intracoronary infusion of antithrombin III during percutaneous transluminal coronary angioplasty. Circulation. 90:1994;2258-2266.